Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics

Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments

Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings

A veteran in cell therapy and oncology commercialisation

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education

Moderna teams up with Recordati to commercialize rare disease therapy

Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA

The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies

Hongene Biotech bags Gates Foundation grant to boost global mRNA vaccine access

Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment

Telangana unveils ambitious next-gen Life Sciences Policy at Davos

A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics